Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2010, Article ID 178372, 14 pages
http://dx.doi.org/10.1155/2010/178372
Review Article

Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin Pumps

Laboratory of Applied Bioorganic Chemistry, Chemical Engineering Faculty, Aristotle University, 54124 Thessaloniki, Greece

Received 2 November 2009; Accepted 1 February 2010

Academic Editor: Ryichi Kikkawa

Copyright © 2010 Vasiliki Valla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Brunton, “Beyond glycemic control: treating the entire type 2 diabetes disorder,” Postgraduate Medicine, vol. 121, no. 5, pp. 68–81, 2009. View at Google Scholar
  2. M. E. Cobble and A. L. Peters, “Clinical practice in type 2 diabetes: after metformin and lifestyle, then what?” The Journal of Family Practice, vol. 58, supplement 11, pp. S7–S14, 2009. View at Google Scholar
  3. J. Philippe and D. Raccah, “Treating type 2 diabetes: how safe are current therapeutic agents?” International Journal of Clinical Practice, vol. 63, no. 2, pp. 321–332, 2009. View at Publisher · View at Google Scholar · View at PubMed
  4. United Kingdom Prospective Diabetes Study Group, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” Lancet, vol. 352, pp. 837–853, 1998. View at Google Scholar
  5. E. Selvin, K. Wattanakit, M. W. Steffes, J. Coresh, and A. R. Sharrett, “HbA1c and peripheral arterial disease in diabetes: the atherosclerosis risk in communities study,” Diabetes Care, vol. 29, no. 4, pp. 877–882, 2006. View at Google Scholar
  6. M. Meier and M. Hummel, “Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies,” Vascular Health and Risk Management, vol. 5, pp. 859–871, 2009. View at Google Scholar
  7. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “American diabetes association; european association for study of diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of diabetes,” Diabetes Care, vol. 32, no. 1, pp. 193–203, 2009. View at Google Scholar
  8. D. M. Nathan, J. B. Buse, M. B. Davidson et al., “American diabetes association and the European association for the study of diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy : aconsensus statement from the,” Diabetologia, vol. 52, no. 1, pp. 17–30, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. British Cardiac Society, British Hypertension Society, Diabetes UK et al., “JBS 2: prevention of cardiovascular disease in clinical practice,” Heart, vol. 91, supplement 5, pp. v1–v52, 2005. View at Google Scholar
  10. L. Rydn, E. Standl, M. Bartnik et al., “Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD),” European Heart Journal, vol. 28, no. 1, pp. 88–136, 2007. View at Publisher · View at Google Scholar · View at PubMed
  11. K. M. Fox, R. A. Gerber, B. Bolinder, J. Chen, and S. Kumar, “Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002,” Clinical Therapeutics, vol. 28, no. 3, pp. 388–395, 2006. View at Publisher · View at Google Scholar · View at PubMed
  12. W. C. Knowler, S. E. Fowler, R. F. Hamman et al., “10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study,” The Lancet, vol. 374, no. 9702, pp. 1677–1686, 2009. View at Publisher · View at Google Scholar
  13. T. D. Giles, “Prevention of type 2 diabetes mellitus to reduce cardiovascular morbidity and mortality: a review of the evidence,” Journal of Clinical Hypertension, vol. 11, no. 9, pp. 512–519, 2009. View at Publisher · View at Google Scholar · View at PubMed
  14. M. E. Cobble, “Initiating and intensifying insulin therapy for type 2 diabetes: why, when, and how,” American Journal of Therapeutics, vol. 16, no. 1, pp. 56–64, 2009. View at Publisher · View at Google Scholar · View at PubMed
  15. W. C. Hsu, “Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals,” Southern Medical Journal, vol. 102, no. 1, pp. 67–76, 2009. View at Publisher · View at Google Scholar · View at PubMed
  16. D. Kerr, “Individualism and insulin pump therapy,” Diabetologia, vol. 52, no. 2, pp. 362–363, 2009. View at Publisher · View at Google Scholar · View at PubMed
  17. D. S.H. Bell, “Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised?” Drugs, vol. 67, no. 13, pp. 1813–1827, 2007. View at Publisher · View at Google Scholar
  18. B. Sheldon, D. Russell-Jones, and J. Wright, “Insulin analogues: an example of applied medical science,” Diabetes, Obesity and Metabolism, vol. 11, no. 1, pp. 5–19, 2009. View at Publisher · View at Google Scholar · View at PubMed
  19. S. K. Garg, I. B. Hirsch, and J. S. Skyler, “Insulin glargine and cancer-an unsubstantiated allegation,” Diabetes Technology and Therapeutics, vol. 11, no. 8, pp. 473–476, 2009. View at Publisher · View at Google Scholar · View at PubMed
  20. K. Eckardt and J. Eckel, “Insulin analogues: action profiles beyond glycaemic control,” Archives Physiol Biochem, vol. 114, no. 1, pp. 45–153, 2008. View at Google Scholar
  21. D. Giugliano, A. Ceriello, E. Razzoli, and K. Esposito, “Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus,” Clinical Drug Investigation, vol. 28, no. 4, pp. 199–210, 2008. View at Publisher · View at Google Scholar
  22. T. M. Chapman, S. Noble, and K. L. Goa, “Spotlight on insulin aspart in type 1 and 2 diabetes mellitus,” Treatments in Endocrinology, vol. 2, no. 1, pp. 71–76, 2003. View at Google Scholar
  23. R. H. A. Becker, “Insulin glulisine complementing basal insulins: a review of structure and activity,” Diabetes Technology and Therapeutics, vol. 9, no. 1, pp. 109–121, 2007. View at Publisher · View at Google Scholar · View at PubMed
  24. K. P. Garnock-Jones and G. L. Plosker, “Insulin glulisine: a review of its use in the management of diabetes mellitus,” Drugs, vol. 69, no. 8, pp. 1035–1057, 2009. View at Publisher · View at Google Scholar · View at PubMed
  25. E. G. Hagenmeyer, P. K. Schädlich, A. D. Köster, F.-W. Dippel, and B. Häussler, “Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues,” Deutsche Medizinische Wochenschrift, vol. 134, no. 12, pp. 565–570, 2009. View at Publisher · View at Google Scholar · View at PubMed
  26. M. A. Elrishi, J. Jarvis, K. Khunti, and M. J. Davies, “Insulin glargine and its role in glycaemic management of Type 2 diabetes,” Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 8, pp. 1099–1110, 2008. View at Publisher · View at Google Scholar · View at PubMed
  27. J. Morales, “Defining the role of insulin detemir in basal insulin therapy,” Drugs, vol. 67, no. 17, pp. 2557–2584, 2007. View at Google Scholar
  28. M. C. Riddle, J. Rosenstock, and J. Gerich, “The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients,” Diabetes Care, vol. 26, no. 11, pp. 3080–3086, 2003. View at Publisher · View at Google Scholar
  29. H. C. Gerstein, J.-F. Yale, S. B. Harris, M. Issa, J. A. Stewart, and E. Dempsey, “A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (implementing new strategies with Insulin glargine for hyperglycaemia treatment) Study,” Diabetic Medicine, vol. 23, no. 7, pp. 736–742, 2006. View at Publisher · View at Google Scholar · View at PubMed
  30. J. Rosenstock, D. Sugimoto, P. Strange, J. A. Stewart, E. Soltes-Rak, and G. Dailey, “Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients,” Diabetes Care, vol. 29, no. 3, pp. 554–559, 2006. View at Google Scholar
  31. K. Horvath, K. Jeitler, A. Berghold, and S. H. Ebrahim, “Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews, vol. 18, no. 2, Article ID CD005613, 2007. View at Publisher · View at Google Scholar
  32. R. Qayyum, S. Bolen, N. Maruthur et al., “Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes,” Annals of Internal Medicine, vol. 149, no. 8, pp. 549–559, 2008. View at Google Scholar
  33. S. C. L. Gough, “A review of human and analogue insulin trials,” Diabetes Research and Clinical Practice, vol. 77, no. 1, pp. 1–15, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. H. Shamoon, H. Duffy, N. Fleischer et al., “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar
  35. H. P. Chase, T. Lockspeiser, B. Peery et al., “The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes,” Diabetes Care, vol. 24, no. 3, pp. 430–434, 2001. View at Google Scholar
  36. M. Monami, N. Marchionni, and E. Mannucci, “Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis,” Diabetes, Obesity and Metabolism, vol. 11, no. 4, pp. 372–378, 2009. View at Publisher · View at Google Scholar · View at PubMed
  37. L. Meneghini, “Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient,” International Journal of Clinical Practice, vol. 62, no. 8, pp. 1255–1264, 2008. View at Publisher · View at Google Scholar · View at PubMed
  38. F. X. Pi-Sunyer, “The effects of pharmacologic agents for type 2 diabetes mellitus on body weight,” Postgraduate Medicine, vol. 120, no. 2, pp. 5–17, 2008. View at Publisher · View at Google Scholar · View at PubMed
  39. M. A. Bush, “Intensive diabetes therapy and body weight: focus on insulin detemir,” Endocrinology and Metabolism Clinics of North America, vol. 36, supplement 1, pp. 33–44, 2007. View at Publisher · View at Google Scholar
  40. A. Dornhorst, H.-J. Lüddeke, C. Koenen et al., “Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE,” Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 75–81, 2008. View at Publisher · View at Google Scholar · View at PubMed
  41. I. Hartman, “Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence,” Clinical Medicine and Research, vol. 6, no. 2, pp. 54–67, 2008. View at Publisher · View at Google Scholar · View at PubMed
  42. G. Scheiner, R. J. Sobel, D. E. Smith et al., “Insulin pump therapy guidelines for successful outcomes,” Diabetes Educator, vol. 35, supplement 2, pp. 29S–41S, 2009. View at Publisher · View at Google Scholar · View at PubMed
  43. H. Hanaire, V. Lassmann-Vague, N. Jeandidier et al., “Treatment of diabetes mellitus using an external insulin pump: the state of the art,” Diabetes and Metabolism, vol. 34, no. 4, supplement 1, pp. 401–423, 2008. View at Publisher · View at Google Scholar · View at PubMed
  44. J. Sherr and W. V. Tamborlane, “Past, present, and future of insulin pump therapy: better shot at diabetes control,” Mount Sinai Journal of Medicine, vol. 75, no. 4, pp. 352–361, 2008. View at Publisher · View at Google Scholar · View at PubMed
  45. L. G. Potti and S. T. Haines, “Continuous subcutaneous insulin infusion therapy: a primer on insulin pumps,” Journal of the American Pharmacists Association, vol. 49, no. 1, pp. 1–13, 2009. View at Google Scholar
  46. R. D. White, “Insulin pump therapy (continuous subcutaneous insulin infusion),” Primary Care, vol. 34, no. 4, pp. 845–871, 2007. View at Publisher · View at Google Scholar · View at PubMed
  47. R. D. R. Liberatore and D. Damiani, “Insulin pump therapy in type 1 diabetes mellitus,” Jornal de Pediatria, vol. 82, no. 4, pp. 249–254, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. T. Ulahannan, N. N. Myint, and K. F. Lonnen, “Making the case for insulin pump therapy,” Practical Diabetes International, vol. 24, no. 5, pp. 252–256, 2007. View at Publisher · View at Google Scholar
  49. N. Jeandidier, J.-P. Rivelineb, N. Tubiana-Rufi et al., “Treatment of diabetes mellitus using an external insulin pump in clinical practice,” Diabetes and Metabolism, vol. 34, no. 4, supplement 1, pp. 425–438, 2008. View at Publisher · View at Google Scholar · View at PubMed
  50. N. Siddiqui, S. Rahman, and A. Nessa, “Development of insulin delivery systems,” Mymensingh Medical Journal, vol. 17, no. 1, pp. 102–110, 2008. View at Google Scholar
  51. H. Shamoon, H. Duffy, N. Fleischer et al., “Implementation of treatment protocols in the diabetes control and complications trial,” Diabetes Care, vol. 18, no. 3, pp. 361–376, 1995. View at Google Scholar
  52. J. Pickup, M. Mattock, and S. Kerry, “Glycemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials,” British Medical Journal, vol. 324, pp. 705–708, 2002. View at Google Scholar
  53. J. Weissberg-Benchell, J. Antisdel-Lomaglio, and R. Seshadri, “Insulin pump therapy: a meta-analysis,” Diabetes Care, vol. 26, no. 4, pp. 1079–1087, 2003. View at Publisher · View at Google Scholar
  54. K. D. Barnard, C. E. Lloyd, and T. C. Skinner, “Systematic literature review: quality of life associated with insulin pump use in type 1 diabetes,” Diabetic Medicine, vol. 24, no. 6, pp. 607–617, 2007. View at Publisher · View at Google Scholar · View at PubMed
  55. J. Colquitt, P. Royle, and N. Waugh, “Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis,” Diabetic Medicine, vol. 20, no. 10, pp. 863–866, 2003. View at Publisher · View at Google Scholar
  56. R. Retnakaran, J. Hochman, J. H. DeVries et al., “Continuous subcutaneous insulin infusion versus multiple daily injections. The impact of baseline A1c,” Diabetes Care, vol. 27, no. 11, pp. 2590–2596, 2004. View at Publisher · View at Google Scholar
  57. R. Retnakaran, J. H. DeVries, H. Hanaire-Broutin, R. J. Heine, V. Melki, and B. Zinman, “Continuous subcutaneous insulin infusion versus multiple daily injections. Modeling predicted benefits in relationship to baseline A1c,” Diabetes Care, vol. 28, no. 7, pp. 1835–1836, 2005. View at Publisher · View at Google Scholar
  58. R. P. L. M. Hoogma, P. J. Hammond, R. Gomis et al., “Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life. Results of the 5-nations trial,” Diabetic Medicine, vol. 23, no. 2, pp. 141–147, 2006. View at Publisher · View at Google Scholar · View at PubMed
  59. B. Bolli, F. Capani, P. Home et al., “Comparison of a multiple daily injection daily with once-daily insulin glargine basal insulin and mealtime lispro, to continuous subcutaneous insulin infusion: a randomised, open, parallel study,” Diabetes, vol. 53, supplement 2, pp. A107–A108, 2004. View at Google Scholar
  60. E. A. Doyle, S. A. Weinzimer, A. T. Steffen, J. A. H. Ahern, M. Vincent, and W. V. Tamborlane, “A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine,” Diabetes Care, vol. 27, no. 7, pp. 1554–1558, 2004. View at Publisher · View at Google Scholar
  61. B. Hirsch, B. Bode, S. Garg et al., “Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII,” Diabetes Care, vol. 28, pp. 533–538, 2005. View at Google Scholar
  62. M. Fahlén, B. Eliasson, and A. Oden, “Optimization of basal insulin delivery in type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine,” Diabetic Medicine, vol. 22, no. 4, pp. 382–386, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. I. Aberle, D. Zimprich, B. Bach-Kliegel et al., “Continuous subcutaneous insulin infusion leads to immediate, stable and long-term changes in metabolic control,” Diabetes, Obesity and Metabolism, vol. 10, no. 4, pp. 329–335, 2008. View at Publisher · View at Google Scholar · View at PubMed
  64. W. V. Tamborlane, K. Swan, K. A. Sikes, A. T. Steffen, and S. A. Weinzimer, “The renaissance of insulin pump treatment in childhood type 1 diabetes,” Reviews in Endocrine and Metabolic Disorders, vol. 7, no. 3, pp. 205–213, 2006. View at Publisher · View at Google Scholar · View at PubMed
  65. S. A. Weinzimer, J. H. Ahern, E. A. Doyle et al., “Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report,” Pediatrics, vol. 114, no. 6, pp. 1601–1605, 2004. View at Publisher · View at Google Scholar · View at PubMed
  66. N. Sulli and B. Shashaj, “Long-term benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes: a 4-year follow-up,” Diabetic Medicine, vol. 23, no. 8, pp. 900–906, 2006. View at Publisher · View at Google Scholar · View at PubMed
  67. B. I. Jakisch, V. M. Wagner, B. Heidtmann et al., “Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years,” Diabetic Medicine, vol. 25, no. 1, pp. 80–85, 2008. View at Publisher · View at Google Scholar · View at PubMed
  68. S. A. Weinzimer, C. Ternand, C. Howard, C.-T. Chang, D. J. Becker, and L. M. B. Laffel, “A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes,” Diabetes Care, vol. 31, no. 2, pp. 210–215, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. J. C. Pickup and A. J. Sutton, “Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion,” Diabetic Medicine, vol. 25, no. 7, pp. 765–774, 2008. View at Publisher · View at Google Scholar · View at PubMed
  70. J. J. F. McVean, J. C. Eickhoff, and M. J. MacDonald, “Factors correlating with improved A1C in children using continuous subcutaneous insulin infusion,” Diabetes Care, vol. 30, no. 10, pp. 2499–2500, 2007. View at Publisher · View at Google Scholar · View at PubMed
  71. R. Hanas and J. Ludvigsson, “Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents,” Pediatric Diabetes, vol. 7, supplement 4, pp. 32–38, 2006. View at Publisher · View at Google Scholar · View at PubMed
  72. S. K. McMahon, F. L. Airey, D. A. Marangou et al., “Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life,” Diabetic Medicine, vol. 22, no. 1, pp. 92–96, 2005. View at Publisher · View at Google Scholar · View at PubMed
  73. P. B. Júlíusson, M. Graue, and T. Wentzel-Larsen, “The impact of continuous subcutaneous insulin infusion on health-related quality of life in children and adolescents with type 1 diabetes,” Acta Paediatrica, vol. 95, no. 11, pp. 1481–1487, 2006. View at Publisher · View at Google Scholar · View at PubMed
  74. L. Opipari-arrigan, E. M. Fredericks, N. Burkhart, L. Dale, M. Hodge, and C. Foster, “Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus,” Pediatric Diabetes, vol. 8, no. 6, pp. 377–383, 2007. View at Publisher · View at Google Scholar · View at PubMed
  75. K. D. Barnard, J. Speight, and T. C. Skinner, “Quality of life and impact of continuous subcutaneous insulin infusion for children and their parents,” Practical Diabetes International, vol. 25, no. 7, pp. 278–284, 2008. View at Publisher · View at Google Scholar
  76. O. Rackham, F. Paize, and A. M. Weindling, “Cause of death in infants of women with pregestational diabetes mellitus and the relationship with glycemic control,” Postgraduate Medicine, vol. 121, no. 4, pp. 26–32, 2009. View at Publisher · View at Google Scholar · View at PubMed
  77. S. Hieronimus, C. Cupelli, A. Bongain, M. Durand-Rèville, F. Berthier, and P. Fènichel, “Pregnancy in type 1 diabetes: insulin pump versus intensified conventional therapy,” Gynecologie Obstetrique Fertilite, vol. 33, no. 6, pp. 389–394, 2005. View at Publisher · View at Google Scholar · View at PubMed
  78. S. G. Gabbe, E. Holing, P. Temple, and Z. A. Brown, “Benefits, risks, costs, and patient satisfaction associated with insulin pump therapy for the pregnancy complicated by type 1 diabetes mellitus,” American Journal of Obstetrics and Gynecology, vol. 182, no. 6, pp. 1283–1291, 2000. View at Publisher · View at Google Scholar · View at PubMed
  79. Gestational Diabetes Mellitus, “American diabetes association publication,” Diabetes Care, vol. 26, supplement 1, pp. S103–S105, 2003. View at Google Scholar
  80. L. Chitayat, L. Jovanovic, and M. Hod, “New modalities in the treatment of pregnancies complicated by diabetes: drugs and devices,” Seminars in Fetal and Neonatal Medicine, vol. 14, no. 2, pp. 72–76, 2009. View at Publisher · View at Google Scholar · View at PubMed
  81. A. Mukhopadhyay, T. Farrell, R. B. Fraser, and B. Ola, “Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials,” American Journal of Obstetrics and Gynecology, vol. 197, no. 5, pp. 447–456, 2007. View at Publisher · View at Google Scholar · View at PubMed
  82. D. Farrar, D. J. Tuffnell, and J. West, “Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes,” Cochrane Database of Systematic Reviews, vol. 18, no. 3, Article ID CD005542, 2007. View at Publisher · View at Google Scholar · View at PubMed
  83. A. St John, W. A. Davis, C. P. Price, and T. M. E. Davis, “The value of self-monitoring of blood glucose: a review of recent evidence,” Journal of Diabetes and Its Complications, vol. 24, no. 2, pp. 129–141, 2010. View at Publisher · View at Google Scholar · View at PubMed
  84. K. D. Kohnert, L. Vogt, P. Augstein et al., “Relationships between glucose variability and conventional measures of glycemic control in continuously monitored patients with type 2 diabetes,” Hormone and Metabolic Research, vol. 41, no. 2, pp. 137–141, 2009. View at Publisher · View at Google Scholar · View at PubMed
  85. G. Reach and C. Choleau, “Continuous glucose monitoring: physiological and technological challenges,” Current Diabetes Reviews, vol. 4, no. 3, pp. 175–180, 2008. View at Publisher · View at Google Scholar
  86. C. De Block, B. Manuel-y-Keenoy, P. Rogiers, P. Jorens, and L. Van Gaal, “Glucose control and use of continuous glucose monitoring in the intensive care unit: a critical review,” Current Diabetes Reviews, vol. 4, no. 3, pp. 234–244, 2008. View at Publisher · View at Google Scholar
  87. T. Battelino and J. Bolinder, “Clinical use of real-time continuous glucose monitoring,” Current Diabetes Reviews, vol. 4, no. 3, pp. 218–222, 2008. View at Publisher · View at Google Scholar
  88. S. L. Ellis, R. G. Naik, K. Gemperline, and S. K. Garg, “Use of continuous glucose monitoring in patients with type 1 diabetes,” Current Diabetes Reviews, vol. 4, no. 3, pp. 207–217, 2008. View at Publisher · View at Google Scholar
  89. R. Hovorka, “Continuous glucose monitoring and closed-loop systems,” Diabetic Medicine, vol. 23, no. 1, pp. 1–12, 2006. View at Publisher · View at Google Scholar · View at PubMed
  90. H. Hanaire, “Continuous glucose monitoring and external insulin pump: towards a subcutaneous closed loop,” Diabetes and Metabolism, vol. 32, no. 5, pp. 534–538, 2006. View at Publisher · View at Google Scholar
  91. I. B. Hirsch, D. Armstrong, R. M. Bergenstal et al., “Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM),” Diabetes Technology and Therapeutics, vol. 10, no. 4, pp. 232–246, 2008. View at Publisher · View at Google Scholar · View at PubMed
  92. G. Sparacino, A. Facchinetti, A. Maran, and C. Cobelli, “Continuous glucose monitoring time series and hypo/hyperglycemia prevention: requirements, methods, open problems,” Current Diabetes Reviews, vol. 4, no. 3, pp. 181–192, 2008. View at Publisher · View at Google Scholar
  93. T. Danne, K. Lange, and O. Kordonouri, “Real-time glucose sensors in children and adolescents with type-1 diabetes,” Hormone Research, vol. 70, no. 4, pp. 193–202, 2008. View at Publisher · View at Google Scholar · View at PubMed
  94. P. Grant, “A new approach to diabetic control: fuzzy logic and insulin pump technology,” Medical Engineering and Physics, vol. 29, no. 7, pp. 824–827, 2007. View at Publisher · View at Google Scholar · View at PubMed
  95. G. M. Steil, K. Rebrin, C. Darwin, F. Hariri, and M. F. Saad, “Feasibility of automating insulin delivery for the treatment of type 1 diabetes,” Diabetes, vol. 55, no. 12, pp. 3344–3350, 2006. View at Publisher · View at Google Scholar · View at PubMed
  96. S. A. Weinzimer, G. M. Steil, K. L. Swan, J. Dziura, N. Kurtz, and W. V. Tamborlane, “Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas,” Diabetes Care, vol. 31, no. 5, pp. 934–939, 2008. View at Publisher · View at Google Scholar · View at PubMed
  97. B. W. Bequette, “A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas,” Diabetes Technology and Therapeutics, vol. 7, no. 1, pp. 28–47, 2005. View at Publisher · View at Google Scholar · View at PubMed
  98. A. I. Silva, A. Norton De Matos, I. G. Brons, and M. Mateus, “An overview on the development of a bio-artificial pancreas as a treatment of insulin-dependent diabetes mellitus,” Medicinal Research Reviews, vol. 26, no. 2, pp. 181–222, 2006. View at Publisher · View at Google Scholar · View at PubMed
  99. B. Thorens, “Development and preclinical assessment of a bioartificial pancreas,” Swiss Medical Weekly, vol. 137, supplement 155, pp. 68S–71S, 2007. View at Google Scholar
  100. E. Renard, G. Costalat, H. Chevassus, and J. Bringer, “Artificial β-cell: clinical experience toward an implantable closed-loop insulin delivery system,” Diabetes and Metabolism, vol. 32, no. 5, pp. 497–502, 2006. View at Google Scholar
  101. N. Erdin, F. Robin, L. Heinemann, D. Brandt, and R. Hovorka, “Further development of artificial pancreas: blocked by patents?” Journal of Diabetes Science and Technology, vol. 2, no. 6, pp. 971–976, 2008. View at Google Scholar
  102. N. Kobayashi, “Bioartificial pancreas for the treatment of diabetes,” Cell Transplantation, vol. 17, no. 1-2, pp. 11–17, 2008. View at Google Scholar